Rocket


Overview
Financials
News + Filings
Key Docs
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Appointed director

OPIANT PHARMACEUTICALS, INC. (LLTP) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/02/2023 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "AMENDED AND RESTATED CERTIFICATE OF INCORPORATION",
"SECOND AMENDED AND RESTATED BYLAWS OF OPIANT PHARMACEUTICALS, INC."
03/01/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
02/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC",
"Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC"
01/09/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/15/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/11/2022 8-K Quarterly results
06/14/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
04/27/2022 8-K Other Events  Interactive Data
Docs: "Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone"
03/15/2022 8-K Results of Operations and Financial Condition  Interactive Data
Docs: "Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update"
01/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/13/2021 8-K Quarterly results
11/12/2021 8-K Quarterly results
Docs: "Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update"
11/08/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose"
07/12/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "2021 Inducement Equity Incentive Plan and Form of Option Agreement thereunder",
"Opiant Pharmaceuticals Announces Appointment of Matthew Ruth"
06/15/2021 8-K Submission of Matters to a Vote of Security Holders
05/11/2021 8-K Quarterly results
04/13/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
01/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/21/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/14/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "ITEM NO. SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT NAME OF OFFEROR OR CONTRACTOR 2 8 CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED PAGE OF OPIANT PHARMACEUTICALS, INC 1530943"
12/10/2020 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
Docs: "Press Release for Opiant Pharmaceuticals, Inc.",
"Note Purchase and Security Agreement, by and among Opiant Pharmaceuticals, Inc. and the parties named therein",
"Registration Rights Agreement, by and among Opiant Pharmaceuticals, Inc. and the parties named therein"
11/18/2020 8-K Other Events
11/12/2020 8-K Quarterly results
Docs: "Press Release of Opiant Press Release of Opiant Pharmaceuticals, Inc., Inc."
10/29/2020 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Master Services Agreement between the Company and AptarGroup, Inc",
"Press release of Opiant Pharmaceuticals, Inc."
08/06/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
06/16/2020 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy